Journal: Science Advances

Article Title: International multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity

doi: 10.1126/sciadv.aeb7039

Figure Lengend Snippet: ( A ) Schematic representation of the pipeline for growth factor candidate selection and cell-based testing. ( B ) Western blot analysis of 11 high-value CFPS-derived growth factors. FGF-1, FGF-2, FGF-10, TNF-α, IL-1β, IFN-γ, and IL-15 were expressed in E. coli BL21(DE3) in-house cell-free lysates, while IL-6, EGF, IGF-1, and IL-3 were expressed in SHuffle-based in-house cell-free lysates. Detection was performed using an anti–His–horseradish peroxidase (HRP) antibody (Ab). Representative data from one of three independent experiments. The molecular weight ladder (in kilodaltons) is shown on the left. ( C ) In vitro proliferation assay comparing on-demand, locally produced in Canada (blue) and commercial (green) FGF-1 growth factors in NIH-3T3 cells. Cells were treated with varying concentrations (1, 5, 10, 50, 500, and 1000 ng/ml). Luminescence was measured using a conventional plate reader (means ± SD, n = 3). ( D ) In vitro proliferation assay comparing on-demand, locally produced (blue) and commercial (green) IL-3 growth factors in TF-1 cells. Cells were treated with varying concentrations (0.025, 0.050, 0.100, 0.5, 1, and 5 ng/ml). Representative data obtained using reagents produced on-site in Canada (means ± SD, n = 2). ( E ) Growth factor expression and cell-based validation in a low-resource setting. In vitro proliferation assay using FGF-1 and NIH-3T3 cells treated with varying concentrations (1, 5, 10, 50, 500, and 1000 ng/ml) of in-house–produced (blue) and commercial (green) growth factors (means ± SD, n = 3). Representative data obtained using reagents produced on-site in Brazil. Relative fold proliferation was plotted relative to untreated, serum-starved cells under the same experimental conditions. Two-way ANOVA determined statistical differences with Šídák’s post hoc multiple comparisons test (ns, P > 0.05; * P < 0.05; *** P < 0.001).

Article Snippet: TF-1 (ATCC; CRL-2003) cells were cultured in RPMI 1640 medium (Gibco).

Techniques: Selection, Western Blot, Derivative Assay, Molecular Weight, In Vitro, Proliferation Assay, Produced, Expressing, Biomarker Discovery

Journal: Blood Neoplasia

Article Title: Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis

doi: 10.1016/j.bneo.2026.100206

Figure Lengend Snippet: Cytotoxicity assessment on JAK2-dependent and non-JAK2–dependent AML cell lines. Quantification of the effects of JAKinibs on the viability of JAK2 dependent cells (on-target: SET2, F36P, TF1) and JAK2 independent cells (off-target: EOL1, MV4-11, MOLM16) in assays using a CellTiter-Glo assay following treatment for 72 hours with JAKinibs at indicated concentrations. C max,ss and C avg,ss per drug are indicated with vertical lines. Values are provided in . AML, acute myeloid leukemia; C avg,ss , average steady-state plasma drug concentration during multiple-dose administration; C max.ss , maximum steady-state plasma drug concentration during a dosage interval; GeoMean, geometric mean.

Article Snippet: JAKinib cytotoxicity was assessed in human SET2 (DSMZ), F36-P (DSMZ), TF1 (ATCC), EOL1 (DSMZ), MV-4-11 (ATCC) and MOLM-16 (DSMZ) cell lines treated with serial dilutions of JAKinibs (0.5nM to 10μM; ).

Techniques: Glo Assay, Clinical Proteomics, Concentration Assay